Physician profile
Ali Ipakchi
NPI 1487618773
$7,154.71
in general payments reported to CMS, 2019-2025
30 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $253 · 2021: $571 · 2022: $997 · 2023: $1,378 · 2024: $1,706 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,554 · Education: $83.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,554.05 |
| Education | $83.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,332.93 | 2020-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $809.26 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $555.70 | 2020-2025 | Acthar |
| Amgen INC. | $400.03 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $385.50 | 2019-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.30 | 2023-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $298.81 | 2019 | |
| Vifor Pharma, INC. | $272.57 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $256.33 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $253.57 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $242.05 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $236.64 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $236.29 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $179.19 | 2022-2024 | Lupkynis |
| Akebia Therapeutics INC | $170.63 | 2019-2025 | Vafseo, Auryxia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $153.35 | 2021-2025 | Givlaari |
| Ani Pharmaceuticals, INC. | $133.62 | 2022 | |
| Opko Pharmaceuticals, LLC | $129.17 | 2019-2024 | Rayaldee |
| Horizon Therapeutics Plc | $126.04 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $119.95 | 2022-2024 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $95.95 | 2023-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $73.62 | 2019-2025 | Ultomiris |
| Acclarent, INC | $73.50 | 2023 | Acclarent Balloon Inflation Device |
| Takeda Pharmaceuticals U.S.A., INC. | $71.59 | 2021-2022 | |
| Biomerieux INC | $61.31 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $44.04 | 2024 | Crysvita |
| Kyowa Kirin, INC. | $41.97 | 2023-2025 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.18 | 2019-2025 | |
| Shield Therapeutics INC | $21.95 | 2023 | Accrufer |
| Shire North American Group INC | $17.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Ipakchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.